Biovail acquires AMPAKINE compounds for treatment of respiratory depression
Font size: A | A | A
7:00 AM ET 3/26/10 | Briefing.com
RELATED QUOTES
4:00 PM ET 3/25/10
Symbol Last % Chg
BVF
16.35 0.00%
Quotes delayed at least 15 minutes
Co announces its subsidiary, Biovail Laboratories International, has acquired certain AMPAKINE compounds, including associated intellectual property, from Cortex Pharmaceuticals, for use in the field of respiratory depression, a brain-mediated breathing disorder. The acquired compounds include the Phase 2 compound CX717, the preclinical compounds CX1763 and CX1942, and the injectable dosage form of CX1739. As part of the acquisition transaction, BLS has also entered into a field limited license agreement with The Regents of the University of California. Under the terms of the asset purchase agreement, BLS has paid an upfront fee of $9 million, expects to pay an additional $1 million upon the completion of a transition period, and could pay up to $15 million in potential milestones contingent on the successful demonstration of the utility of an intravenous formulation of CX717 in treating respiratory depression, the successful completion of a Phase 3 clinical program using an AMPAKINE compound and approval from the FDA. BLS may also owe certain development milestones and/or low single-digit royalties on net sales to third parties.
AI
